Trazodone Pregnancy & Lactation Safety: What the Evidence Actually Shows

How Trazodone Works: Mechanism and Pharmacology

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI). It blocks 5-HT2A and 5-HT2C receptors, inhibits the serotonin transporter (SERT), and at lower doses exerts potent histamine H1 and alpha-1 adrenergic antagonism. That combined profile is what separates it pharmacologically from SSRIs and SNRIs, and it explains both its sedating properties and its reproductive-safety considerations.

Receptor Profile and Why It Matters in Pregnancy

The 5-HT2A antagonism reduces sexual side effects and produces sedation at doses as low as 25 to 100 mg. At antidepressant doses (150 to 400 mg daily), SERT inhibition becomes more prominent. Serotonin receptor expression in human placental tissue has been characterized since the late 1990s, and serotonin itself regulates trophoblast invasion, placental blood flow, and fetal cardiac development. Any serotonergic agent therefore warrants specific scrutiny during gestation, not just generic "antidepressant risk" framing.

Active Metabolite: mCPP

Trazodone is hepatically metabolized by CYP3A4 to meta-chlorophenylpiperazine (mCPP), a 5-HT2C agonist with mild anxiogenic properties. Pregnancy alters CYP3A4 activity, with a 2008 Obstetrics & Gynecology pharmacokinetic study demonstrating up to 35 to 40% induction of CYP3A4 by the third trimester. This means mCPP production may increase during late pregnancy, shifting the effective pharmacodynamic profile of trazodone even if the dose is unchanged.

Dose Forms and Half-Life Considerations

Standard immediate-release tablets are dosed 50 to 150 mg at bedtime for sleep and 150 to 400 mg daily in divided doses for depression. The parent compound half-life is 5 to 9 hours; mCPP half-life is 4 to 14 hours. Extended-release formulations (Oleptro) follow similar metabolic pathways. The relatively short half-life limits accumulation between nightly doses in insomnia regimens, which is clinically relevant when estimating fetal exposure over a 24-hour cycle.

Trazodone in Pregnancy: What the Data Show

No randomized controlled trial has enrolled pregnant women to evaluate trazodone safety. The evidence base consists of registry studies, insurance database cohorts, case series, and spontaneous adverse-event reports. That limitation is not unique to trazodone; it applies to the majority of psychotropic medications used in pregnancy.

Malformation Risk: What the Registries Report

The FDA label for trazodone hydrochloride assigns Pregnancy Category C based on animal data showing fetal resorption in rats and rabbits at doses many times the human therapeutic range. In humans, the evidence is reassuring but limited.

A 2014 analysis using the National Birth Defects Prevention Study examined first-trimester antidepressant exposures in a case-control design. Trazodone-specific numbers were small, but the overall dataset found no statistically significant elevation in major cardiac defects attributable to SARIs as a class. The Centers for Disease Control and Prevention's birth defects surveillance program has similarly not flagged trazodone in sentinel signals.

A Danish registry cohort published in the British Medical Journal examined 1.6 million pregnancies and found that antidepressant exposure during organogenesis (weeks 5 to 10) did not produce a consistent class-level signal for septal defects after propensity-score adjustment, though SSRI-specific data dominated sample sizes. That analysis cautions that trazodone-specific power remained insufficient.

The honest clinical summary: no confirmed teratogenic signal exists in human data, but the studies are underpowered for trazodone specifically. Category C is the correct designation given available evidence.

Neonatal Adaptation Syndrome

Exposure to serotonergic drugs in the third trimester produces neonatal adaptation syndrome (NAS) in approximately 10 to 30% of neonates. Symptoms include jitteriness, irritability, high-pitched cry, feeding difficulty, and transient tachypnea. The syndrome is typically self-limited, resolving within 2 to 14 days without pharmacologic treatment.

The FDA drug safety communication on neonatal adaptation syndrome applies to all serotonergic antidepressants, including trazodone. Neonates delivered from mothers on trazodone should be monitored in a facility equipped to manage these symptoms for at least 48 to 72 hours post-delivery.

Gestational Hypertension and Other Obstetric Outcomes

Trazodone's alpha-1 adrenergic antagonism causes vasodilation and orthostatic hypotension. In pregnancy, this pharmacologic effect could theoretically reduce uteroplacental perfusion pressure, particularly if the mother is already volume-depleted. A 2019 JAMA Psychiatry analysis of antidepressant use across pregnancy trimesters identified confounding by indication as the dominant driver of observed obstetric outcome differences, meaning the untreated psychiatric illness itself contributes more to adverse outcomes than the drug in many cases.

Clinicians should monitor blood pressure at each prenatal visit in patients on trazodone. Symptomatic orthostatic hypotension warrants dose reduction or transition to an agent with a less pronounced adrenergic profile.

Persistent Pulmonary Hypertension of the Newborn (PPHN)

PPHN has been associated with late-pregnancy SSRI use in several studies, with a pooled relative risk of approximately 2.5 to 3.0 in exposed neonates, though absolute risk remains low (estimated 3/1,000 exposed versus 1 to 2/1,000 unexposed). The FDA safety update on PPHN covers serotonergic antidepressants broadly. Trazodone-specific PPHN data are absent from the literature, but the mechanism (elevated serotonin tone causing pulmonary vasoconstriction) is plausible given its SERT inhibitory activity at higher doses.

Trazodone for Insomnia in Pregnancy: A Specific Clinical Problem

Sleep disturbance affects roughly 78% of pregnant women by the third trimester, according to National Sleep Foundation survey data. Trazodone is prescribed off-label for insomnia in the general population despite the fact that only one small controlled trial, Mendelson et al. (J Clin Psychiatry 2005, N=72), specifically evaluated its hypnotic efficacy using polysomnography. That trial found trazodone 50 to 75 mg significantly reduced wake time after sleep onset versus placebo over 2 weeks in adults with primary insomnia, with a mean reduction of 54 minutes versus 19 minutes for placebo (P<0.05).

The pregnancy-insomnia scenario creates a genuine clinical tension. Non-pharmacologic approaches (cognitive behavioral therapy for insomnia, CBT-I) carry no fetal risk and are recommended first-line by ACOG Practice Bulletin 197 on sleep disorders in pregnancy. When CBT-I fails or is unavailable and sleep deprivation is affecting maternal safety (impaired driving, falls, mood dysregulation), pharmacologic options must be weighed individually.

Why Trazodone Over Other Hypnotics in Pregnancy?

Benzodiazepines and Z-drugs (zolpidem, eszopiclone) carry their own pregnancy risk profiles, including concerns about neonatal sedation and potential cleft palate associations with first-trimester benzodiazepine use. Diphenhydramine has a long safety record but limited efficacy for sleep maintenance. Trazodone at low doses (25 to 100 mg) exploits H1 and 5-HT2A antagonism for sedation while avoiding the respiratory-depression profile of benzodiazepines.

An AAFP clinical practice summary on insomnia management notes that evidence for any pharmacologic hypnotic in pregnancy is insufficient to make strong recommendations, and clinician judgment with patient-shared decision-making remains the standard of care.

Dose Selection During Pregnancy

When trazodone is used during pregnancy for insomnia, most clinicians use the lowest effective dose, typically 25 to 75 mg at bedtime. Doses above 150 mg increase SERT inhibition and therefore the serotonergic exposure to the fetus. Trimester timing matters: first-trimester use overlaps with organogenesis, warranting maximum caution; third-trimester use raises NAS risk. A practical approach is to target the shortest duration at the lowest dose, with tapering before the expected delivery date when feasible.

Trazodone and Breastfeeding

Trazodone does transfer into breast milk, but at low levels. The NIH LactMed database entry for trazodone reports a relative infant dose (RID) of approximately 1 to 3% across available case reports and small pharmacokinetic studies. An RID below 10% is generally considered acceptable for most medications in lactating mothers, a threshold established by Thomas Hale in Medications and Mothers' Milk and referenced in multiple lactation-pharmacology guidelines.

Pharmacokinetic Data in Lactation

A frequently cited case report published in the American Journal of Psychiatry measured trazodone and mCPP concentrations in breast milk and matched infant serum samples. The infant serum level was undetectable at standard analytical sensitivity, with an estimated RID of 2.8%. The original case-series pharmacokinetic data provide the primary quantitative basis for current lactation guidance.

Peak trazodone milk concentration occurs approximately 2 hours post-dose. Mothers who wish to minimize infant exposure can nurse immediately before taking their bedtime dose and skip or pump-and-discard the early morning feeding. This "peak-avoidance" strategy exploits the drug's relatively short half-life and is commonly recommended in lactation pharmacology practice, though its clinical benefit has not been formally validated in a trial.

Infant Monitoring During Maternal Trazodone Use

Reported infant effects during maternal trazodone use include drowsiness and reduced feeding frequency. These effects are uncommon at doses below 100 mg but warrant surveillance. ACOG Committee Opinion 723 on pharmacologic treatment of insomnia during pregnancy and lactation advises monitoring the nursing infant for sedation, adequate weight gain, and normal developmental milestones whenever any sedating agent is prescribed postpartum.

The mCPP metabolite also transfers into milk. Its anxiogenic and serotonergic properties are a theoretical concern, though no adverse infant outcomes attributable to mCPP exposure via breast milk appear in the published literature as of mid-2025.

Alternatives Worth Considering

Sertraline has the most extensive lactation safety dataset of any antidepressant, with LactMed reporting RID values of 0.4 to 2.2% and undetectable or very low infant serum levels in most studies. For a postpartum patient with comorbid depression and insomnia, sertraline may offer a better-characterized lactation profile than trazodone, though trazodone may be preferred when sedation is specifically needed and the patient is not depressed.

Risk Stratification and Clinical Decision Framework

The decision to continue, initiate, or discontinue trazodone during pregnancy or lactation depends on four intersecting variables: the severity of the underlying condition being treated, gestational timing, the dose required for symptom control, and the availability of non-pharmacologic alternatives.

Trimester-by-Trimester Considerations

First trimester (weeks 1 to 13): Organogenesis is the highest-risk window for structural teratogenicity. If trazodone is being used for insomnia and CBT-I has not been tried, this is the moment to attempt non-pharmacologic transition. If trazodone is treating major depressive disorder or PTSD at doses required for psychiatric stability, abrupt discontinuation carries its own maternal and fetal risk. A 2006 JAMA study (N=201) found that pregnant women who discontinued antidepressants relapsed at a rate 5 times higher than those who continued, with relapse carrying documented risks of poor nutrition, substance use, and preterm birth.

Second trimester (weeks 14 to 27): Organogenesis is largely complete. Fetal neurodevelopment becomes the primary concern. Dose optimization toward the minimum effective dose is appropriate. No trazodone-specific second-trimester fetal neurodevelopment data exist; extrapolation from SSRI cohort studies suggests no detectable IQ or behavioral deficit at therapeutic exposures.

Third trimester (weeks 28 to 40): NAS risk increases with gestational age. Consider taper to the lowest effective dose 2 to 4 weeks before the estimated delivery date when clinically feasible. Do not taper against the patient's psychiatric stability.

The Untreated Illness Calculation

Untreated depression in pregnancy is associated with preterm birth (adjusted OR approximately 1.39 in a 2013 BMJ meta-analysis), low birth weight, impaired mother-infant bonding, and postpartum depression escalation. Presenting only the drug's risks without quantifying the risks of the untreated condition distorts the clinical picture. Shared decision-making should include both sides of that equation.

Guidance from Professional Organizations

ACOG, the American College of Obstetricians and Gynecologists, states in Practice Bulletin 92 on use of psychiatric medications during pregnancy and lactation that "the risks of untreated psychiatric illness are significant and may outweigh the potential risks of medication exposure." The document recommends against routine discontinuation of effective antidepressant therapy solely because of pregnancy.

The Academy of Breastfeeding Medicine's Protocol 18 on use of antidepressants in breastfeeding mothers, available through PubMed, categorizes trazodone as "probably compatible" with breastfeeding and advises clinical monitoring over blanket avoidance.

The WHO Model List of Essential Medicines does not list trazodone but does list amitriptyline for depression, reflecting the limited global evidence base for trazodone in general, not a specific pregnancy prohibition.

Practical Clinical Instructions

When a pregnant or breastfeeding patient is taking trazodone, the following steps reflect current evidence-based clinical standards.

Prenatal Management Checklist

Before continuing trazodone through pregnancy, clinicians should confirm the indication, document the risk-benefit discussion in the chart, and establish a lowest-effective-dose target. Order a baseline fetal anatomy ultrasound at 18 to 20 weeks. Coordinate with the obstetric team for neonatal monitoring notifications if trazodone continues into the third trimester. If the dose exceeds 150 mg daily during the third trimester, the neonatology team should be informed before delivery.

Postpartum and Lactation Checklist

At the first postpartum visit (typically 2 to 6 weeks), assess infant weight gain, feeding frequency, and maternal mood. If the infant appears sedated or feeding frequency drops below 8 times per 24 hours, review trazodone dose and consider timing adjustment or transition. For infants born premature or with hepatic immaturity, the RID calculation may underestimate actual exposure risk, and a lower threshold for dose adjustment is appropriate.